January 21, 2014

What key reimbursement changes will affect your lab?

BY Dr. Keith J. Kaplan

xifin

Can your lab survive significant reductions?

Reimbursement and bundling changes finalized for 2014 will have a big impact on laboratory and pathology providers. Fee schedule outcomes have been alarming and appear to be setting a trend for the future. Many of these changes threaten operating budgets and are jeopardizing the actual survival of some clinical laboratories. XIFIN is pleased to share with you an upcoming webinar on this topic hosted by The Pathology Blawg.

Thursday, January 23, 2014
11:00am PT / 2:00pm ET
Rina Wolf, Vice President of Commercialization Strategies, Consulting, and Industry AffairsXIFIN, Inc. and Diana Voorhees, Principal and CEO, DV & Associates will provide insights into Medicare’s most recent modifications to molecular pathology billing and coding.


Find out what’s changed, what hasn’t, and how your laboratory can adapt to these changes. You’ll learn what you can do to keep revenue levels up and avoid non-compliance issues. Here is just some of what you’ll learn during this in-depth 90-minute conference:

  • Strategies for helping your lab survive the new pricing.
  • How to find potential opportunities for your lab despite the new pricing.
  • Additional coding changes you can expect in 2014—and how to ensure accurate reporting once they’ve been implemented.
  • Case-study examples of current coding, billing, and reimbursement practices compared with what you’ll need to do in 2014.
Whether you’re a pathologist, billing specialist, laboratory manager or administrator—anyone who’s concerned about how Medicare and commercial payer changes to molecular pathology billing and coding could affect the very survival of your laboratory or pathology group—this is one webinar you can’t afford to miss.

 

OR

platinum partners

gold partners

Silver Partners

Media Partners